prostate-cancer
This systematic review and meta-analysis found that pre-treatment MRI in men undergoing radical prostatectomy provides independent prognostic value for oncological outcomes beyond standard clinical and pathological staging. MRI can assess extracapsular extension, seminal vesicle invasion, and lymph…
breast-cancer
Older radiation techniques for left-sided breast cancer inadvertently exposed the heart to significant doses, raising cardiovascular disease risk years later. This study examined whether modern external beam radiation therapy (EBRT) techniques—using more precise delivery methods—have reduced this…
blood-cancer
Therapy-related acute myeloid leukemia (tAML) arises as a secondary malignancy from cancer treatments (chemotherapy, radiation). This Japanese study found that tAML incidence increased gradually but steadily over the past three decades, with rates almost tripling—driven by the growing population of…
other-cancer
Obesity is a major cancer risk factor and also impairs survival after diagnosis. This expert commentary calls for integrating the most effective obesity treatments—bariatric surgery and GLP-1 receptor agonists (like semaglutide/Ozempic)—into standard cancer survivorship care.
colorectal-cancer
Current guidelines recommend surveillance colonoscopy for patients with prior adenomas. This large study found that older adults with adenoma detected at prior colonoscopy had higher rates of colorectal cancer diagnosis and death than those without adenoma. However, the absolute cumulative…
other-cancer
While the HPV vaccine has been well-established in women, evidence for cancer protection in males has been more limited. This large retrospective cohort study found that the 9-valent HPV vaccine was associated with significantly lower risk of HPV-related cancers in adolescent males and young men.
ovarian-cancer
Platinum-resistant ovarian cancer has a median OS of less than 12 months with standard chemotherapy and few effective options. The ROSELLA trial tested a novel regimen combining niraparib (PARP inhibitor) with dostarlimab (anti-PD-1 antibody) in platinum-resistant disease, and an updated analysis…
ovarian-cancer
Low-grade serous ovarian cancer (LGSOC) is chemotherapy-resistant in many patients. The NRG-GY019 trial compared single-agent MEK inhibitor (trametinib) to combination chemotherapy in LGSOC. While the overall trial result was negative (combination chemotherapy did not demonstrate clear…
endometrial-cancer
Advanced or metastatic endometrial cancer with HER2 expression has limited treatment options. Phase II trial data reported at the Society of Gynecologic Oncology (SGO) meeting showed that an investigational antibody-drug conjugate (ADC)—trastuzumab deruxtecan—achieved response rates of up to 70% in…
blood-cancer
Leukemic stem cells (LSCs) drive AML relapse by resisting treatments targeting bulk tumor cells. This study found LSCs are specifically dependent on the PI3K alpha isoform (P110α). When PI3K is inhibited in AML cells, a compensatory resistance mechanism emerges: EZH2 protein is downregulated, and…
other-cancer
Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, and Notch signaling is frequently altered in it. Using transgenic animal models, advanced imaging, and next-generation sequencing, this study mapped Notch pathway dysregulation in OSCC development and progression.
pancreatic-cancer
Predicting lymph node metastasis (LNM) in pancreatic ductal adenocarcinoma (PDAC) before surgery from CT scans is difficult due to low sensitivity and inter-institutional heterogeneity. This retrospective multi-center study of 546 patients (3 institutions) developed a federated deep learning…
